For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | - | 0* | - | - |
| Research and development | 13,584 | 35,389* | 17,938 | 32,198 |
| General and administrative | 8,188 | 11,629* | 10,331 | 13,394 |
| Total operating expenses | 21,772 | 47,017* | 28,269 | 45,592 |
| Loss from operations | -21,772 | -47,017* | -28,269 | -45,592 |
| Interest and other income (expense), net | 1,732 | 2,590* | 2,783 | 3,101 |
| Interest expense | 0 | 123* | 815 | 809 |
| Loss on extinguishment of debt (note 7) | - | -457* | - | - |
| Net loss | -20,040 | -45,007* | -26,301 | -43,300 |
| Net unrealized (loss) on short-term investments | -326 | -84 | 35 | -160 |
| Total other comprehensive loss | - | -84* | - | - |
| Comprehensive loss | -20,366 | -45,091 | -26,266 | -43,460 |
| Basic EPS | -0.32 | -0.735 | -0.43 | -0.71 |
| Diluted EPS | -0.32 | -0.735 | -0.43 | -0.71 |
| Basic Average Shares | 61,803,467 | 61,308,003 | 61,406,475 | 61,386,183 |
| Diluted Average Shares | 61,803,467 | 61,308,003 | 61,406,475 | 61,386,183 |
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)